Edina Cenko/Redcliffe Cardiology and Erik Stroes/amsterdamumc.nl
Sep 13, 2026, 16:51
Edina Cenko: AZURE-HeFH Highlights the LDL-C Treatment Gap in HeFH
Edina Cenko, Past-Chairperson ESC Working Group on Coronary Pathophysiology and Microcirculation at European Society of Cardiology, shared on LinkedIn:
“Presented by Erik Stroes at ESC Congress 2026, baseline cohort data from the Phase 3 AZURE-HeFH trial evaluating the novel oral PCSK9 inhibitor laroprovstat vs placebo.
Lifelong cumulative exposure makes aggressive LDL-C lowering essential in HeFH—yet less than 25% hit guideline targets on conventional oral LLT.
- N is 472 genetically or clinically confirmed HeFH participants
- Approximately 21% with prior ASCVD
- 94% on statins (more than 80% high-intensity) and 73.1% on ezetimibe
- Mean baseline LDL-C: 2.95 mmol/L despite intensive combination background therapy
These findings underline the profound implementation gap in HeFH.
Looking forward to primary 12-week and 52-week safety or efficacy outcomes.”
Other posts featuring Edina Cenko on Hemostasis Today.
-
Oct 28, 2026, 14:56Elizabeth Shirley: COVID-19 Vaccines, Spike Protein and Nitric Oxide Bioavailability
-
Oct 28, 2026, 14:39David Ledger: Anticoagulation Advances as Factor XIa Inhibition Reaches a New Milestone
-
Oct 28, 2026, 14:37Advancing Liver Health in Haemophilia Care – EAHAD
-
Oct 28, 2026, 14:34The Changing Landscape of Anticoagulant Therapy – ISTH
-
Oct 28, 2026, 14:17Clusterin Regulates von Willebrand Factor Multimer Stability Through ADAMTS13 Inhibition
-
Oct 28, 2026, 14:14Mina Jarrahi: Platelet-Rich Fibrin for Periodontal Regeneration
-
Oct 28, 2026, 14:06Mohammed Alo: A Stent Treats the Blockage, Not the Underlying Disease
-
Oct 28, 2026, 13:58Vladimir Lemaire: When Blood Clots Affect Elite Athletes
-
Oct 28, 2026, 13:27M. Alejandro Mosso-Pani: Dengue in Florida – Why Platelet Function Matters